Next in Nano
The Nanotechnology Characterization Laboratory selects Curadigm’s Nanoprimer technology for a characterization & development collaboration
Register for free to listen to this article
Listen with Speechify
0:00
5:00
PARIS—Curadigm, a wholly-owned subsidiary of Nanobiotix, has announced the selection of its Nanoprimer technology by the National Cancer Institute (NCI)’s Nanotechnology Characterization Laboratory (NCL) for characterization, based on the technology’s potential to significantly impact treatments in multiple disease indications — including cancer.
“The selection of our nanoprimer by the NCL is a major step for Curadigm. The standardized cascade assay developed by the NCL is a great opportunity to accelerate the development of the Nanoprimer by providing additional data about its physico-chemical properties, safety and mechanism of action that will facilitate regulatory review,” noted Matthieu Germain, chief executive officer of Curadigm. “The results generated through this collaboration will also be instrumental in supporting our discussions with partners to develop their therapeutics with the Nanoprimer.”
According to Curadigm, the broad utility of the Nanoprimer technology is due to its unique nanomedicine approach, which improves therapeutic action without modifying the therapeutic in any way. The Nanoprimer is administered intravenously just prior to a therapeutic, and it specifically and transiently occupies the liver pathways responsible for clearance, acting rapidly to temporarily occupy the Kupffer and liver sinusoidal endothelial cells.
The precision-based approach leads to enhanced systemic bioavailability for increased therapeutic action. It temporarily increases a therapeutic’s bioavailability and subsequent accumulation in target tissue. This mechanism, which targets the universal upstream pathways involved in intravenous drug clearance, means that the Nanoprimer can be used in combination with multiple classes of nanomedicines, including nucleic acid and small molecule therapeutics or gene editing technologies.
Through this collaboration, the NCL will perform in-depth preclinical characterizations. These studies will support the Nanoprimer’s development and advancement towards filing an Investigational New Drug (IND) with the U.S. Food and Drug Administration (FDA) and future clinical development. This work will also support ongoing and future collaborations combining the Nanoprimer with therapeutics across diverse clinical indications.
The NCL was established to study the use of nanoparticles and nanomedicines to advance cancer research and to accelerate the development of promising and safe nanotechnology-based cancer therapeutics. The program provides preclinical testing and services on a competitive acceptance basis to companies, such as Curadigm, and is working in concert with other U.S. agencies such as the FDA to accelerate the use of nanomedicines from early-stage development to clinical applications.
